reports
- Martin Marandon-Carlhian
- Stephane Houri
BE Semiconductor Industries : Weak Q1 2024 orders and Q2 guidance poin...
>Q1 2024 results below expectations, with a disappointing order intake - BESI reported its Q1 2024 results which were below expectations, notably on the order intake. Revenues were € 146m, down 8% q-o-q and up 10% y-o-y, due primarily to lower shipments for high-performance computing and automotive end-user markets, partially offset by higher shipments for high-end mobile applications. They were in line with the consensus at € 147m (vs guidance at a q-o-q decrease of ...
- Anis Zgaya
- Louis Boujard
- CFA
Befesa : Q1 in line and 2024 guidance slightly cautious
>Q1 results in line at EBITDA level - This morning, Befesa published its Q1 results, which were in line with consensus expectations. Thegroup's revenue was € 298m, down 7%. EBITDA was € 49m, -3% y-o-y and in line with the company-compiled consensus at € 48m and ODDO BHF and FactSet consensus at € 50m. Net profit came in at € 9.5m below the FactSet consensus forecast at € 14m, due to higher financial interests and higher depreciations than expected. The group's p...
- Martin Marandon-Carlhian
- Stephane Houri
BE Semiconductor Industries : Weak Q1 2024 orders and Q2 guidance poin...
>Q1 2024 results below expectations, with a disappointing order intake - BESI reported its Q1 2024 results which were below expectations, notably on the order intake. Revenues were € 146m, down 8% q-o-q and up 10% y-o-y, due primarily to lower shipments for high-performance computing and automotive end-user markets, partially offset by higher shipments for high-end mobile applications. They were in line with the consensus at € 147m (vs guidance at a q-o-q decrease of ...
- Damien Choplain
- Martial Descoutures
AstraZeneca : Very reassuring Q1 supports 2024 targets
>Symbicort and Farxiga lead the way - AZN has reported much stronger than expected Q1 2024 results, mainly thanks to Farxiga and Symbicort. Revenue increased by 19% at constant exchange rates, boosted by CVRM (cardio and metabolism) and Oncology. Sales came out 7% higher than expected. Although penalised by a recent reduction in prices for Tagrisso (June 23), Imfinzi (February 24) and Faslodex in China (November 23), revenue in China increased by 13%. However, th...
- Emmanuel Matot
2023 S&M Postviews: make or break
>Overall satisfactory 2023 results – entry into recession in Q4 but good margin resilience - Forsee Power has just closed the 2023 publication period for our universe of S&M Cap companies in France (annual sales < € 5bn). Despite a high comparison base, sales and margins continued to grow. However, there were two opposing half-years, with a very dynamic H1 and an H2 marking a negative break. Regarding sales, after the 2021 and 2022 financial years of strong post...
- Olfa Taamallah
- Yan Derocles
Wizz Air : Reassuring trading update for FY 2024
>FY 2024 pretty much in line with expectations - Wizz Air has just released an unaudited post-close trading update for the FY to end-March 2024. Net income is expected in the range of € 350 - 370m for FY, in line with guidance. We were expecting € 357m and the Visible Alpha consensus €352m. Total revenue is expected to be in the range of € 5,050 - 5,100m (ODDO BHF: € 5,165m, VA € 5,154m) reflecting stronger ticket revenue and pricing, partially offset by softer ...
- Damien Choplain
- Martial Descoutures
Sanofi : Q1 2024 passes without a hitch
>A little better than expected - Sanofi has reported this morning Q1 2024 results a little above forecasts at the level of sales and EPS. As expected, Sanofi suffered from a deeply negative forex effect (-4.3% on the topline and -10.2% on the bottom line).In short, total group sales came to € 10.464 bn vs € 10.272 bn (+2.4%; +6.7% at cc), core EBIT to € 2.843 bn vs € 2.748 bn est. (-14.7%; -4.2% at cc) and core EPS to € 1.78 vs € 1.71 est., down 7.4% at cc (sour...
- Emmanuel Matot
X-FAB : 2024 guidance points to a sharp upturn in H2
>Q1 results at the lower end of guidance - X-Fab published its 2024 Q1 results. They come in mixed, with revenues up by only 4% to $ 216m (+5% excluding IFRS 15) and an EBITDA margin down by 430bp to 23.6% (24.0% excluding IFRS 15), i.e. EBITDA down by 12% to $ 51m. These results stand at the lower end of guidance (revenues = $ 215-225m and EBITDA margin = 24-27% => EBITDA = $ 52-58m) shy of consensus (revenues = $ 221m and margin EBITDA = 25.8% => EBITDA = $ 57m...
- Anis Zgaya
- Louis Boujard
- CFA
Befesa : Q1 in line and 2024 guidance slightly cautious
>Q1 results in line at EBITDA level - This morning, Befesa published its Q1 results, which were in line with consensus expectations. Thegroup's revenue was € 298m, down 7%. EBITDA was € 49m, -3% y-o-y and in line with the company-compiled consensus at € 48m and ODDO BHF and FactSet consensus at € 50m. Net profit came in at € 9.5m below the FactSet consensus forecast at € 14m, due to higher financial interests and higher depreciations than expected. The group's p...
- Martial Descoutures
- Oussema Denguir
Adocia : 2024, a potentially transforming year for Adocia
>Operational cash burn down significantly - Yesterday evening, Adocia published its FY 2023 figures. Operating profit over the period was € 6m (vs € 17.3m in 2022, including a milestone payment of € 4.8m received as part of its partnership agreement in China). Underlying operating charges were down 31% to € 20.3m, driven by the reduction in R&D charges to € 14.8m (vs € 25.9m in 2022). This resulted in an operating loss of -€ 14.2m (vs -€ 12.9m previously).The cas...
- Damien Choplain
- Martial Descoutures
AstraZeneca : Un T1 extrêmement rassurant confirmant les ambitions 202...
>Symbicort et Farxiga mènent la danse - AZN vient de publier ses résultats du T1 24 qui se révèlent nettement supérieurs aux attentes du fait notamment de Farxiga et Symbicort. Les revenus sont en hausse de 19% à tcc tirés par sa franchise CVRM (cardio metabolique) et Oncologie. Les ventes ressortent ainsi 7% au-dessus des attentes. Bien que pénalisée par une baisse de prix récentes de Tagrisso (Juin 23), Imfinzi (Fevr 24) et Faslodex en Chine (Nov 23), la Chine est e...
- Martial Descoutures
- Oussema Denguir
Cosmo Pharmaceuticals : Change of management
>Giovanni Di Napoli to be group CEO - Cosmo Pharmaceuticals this morning announced the appointment of Giovanni Di Napoli as CEO, to replace Alessandro Della Chà. The appointment takes effect at the AGM scheduled for 24 May. This appointment follows the Capital Market Day in March which set out the next stages for the company and its ambitions. Mr Di Napoli is very familiar with the GI Genius platform, coming from Medtronic where he occupied several management pos...
- Anis Zgaya
- Louis Boujard
- CFA
La Française de l'Energie : Q3 sales below our estimate, 2024 estimate...
>Q3 2024 sales lower than expected - Yesterday evening La Française de l’Energie reported revenue for Q3 2023-2024 (January to March) which came to € 9.2m, below our estimate of € 10.5m. Revenue fell 11.5% vs Q3 2022-2023 and was in line with Q2 2024 (€ 9.5m). By business, electricity revenue came to € 5.8m, down 13% vs Q3 2023 (€ 6.7m) hurt by lower prices that were partly offset by volume growth. Gas revenue reached € 2.7m vs € 3.2m in Q3 2023 and € 3m in Q2 2024, a...
- Emmanuel Matot
X-FAB : Des guidances 2024 impliquant une nette amélioration au S2
>Résultats T1 dans le bas des guidances - X-Fab vient de publier ses résultats au titre du T1 2024. Ils ressortent mitigés, avec un CA en croissance de seulement +4% à 216 M$ (+5% hors IFRS 15) et une marge EBITDA en baisse de 430 pb à 23.6% (24.0% hors IFRS 15), soit un EBITDA en retrait de 12% à 51 M$. Ses résultats se situent dans le bas des guidances (CA = 215-225 M$ et marge EBITDA = 24-27% => EBITDA = 52-58 M$) et s’avèrent inférieures au consensus (CA = 22...
- Martin Marandon-Carlhian
- Stephane Houri
Aixtron SE : Q1 24 orders and Q2 guidance below expectations, 2024 tar...
>Q1 2024 results below expectations, with a weaker-than-expected order intake - This morning, Aixtron reported its Q1 2024 results which were below expectations, with a weaker-than-expected order intake. The order intake was € 120m, down 14% y-o-y, 21% below the Visible Alpha consensus at € 153m and our estimates at € 150m, with Micro LED applications accounting for 37% of the equipment order intake. Revenues totalled € 118m, up 53% y-o-y above the consensus at € 111m...
- Martin Marandon-Carlhian
- Stephane Houri
Aixtron SE : Q1 24 orders and Q2 guidance below expectations, 2024 tar...
>Q1 2024 results below expectations, with a weaker-than-expected order intake - This morning, Aixtron reported its Q1 2024 results which were below expectations, with a weaker-than-expected order intake. The order intake was € 120m, down 14% y-o-y, 21% below the Visible Alpha consensus at € 153m and our estimates at € 150m, with Micro LED applications accounting for 37% of the equipment order intake. Revenues totalled € 118m, up 53% y-o-y above the consensus at € 111m...
- Damien Choplain
- Martial Descoutures
Sanofi : Le T1 2024 passe sans encombre
>Un peu supérieur aux attentes - Sanofi publie ce matin ses résultats du T1 24 qui s’avèrent un peu au-dessus des attentes au niveau des ventes et de son BPA. Comme attendu Sanofi bénéficie d’un effet changes très négatif (-4.3% en topline et -10.2% en bottom line). Brièvement, les ventes totales du groupe ressortent à 10 464 M€ vs 10 272 M€e (+2.4% ; +6.7% à tcc), son core EBIT à 2 843 M€ vs 2 748 M€e (-14.7% ; -4.2% tcc) pour un Core BPA de 1.78 € vs 1.71 €e e...
- Martial Descoutures
- Oussema Denguir
Cosmo Pharmaceuticals : Changement de management
>Mr Di Napoli devient CEO du groupe - Cosmo Pharmaceuticals annonce ce matin la nomination de Giovanni Di Napoli au poste de CEO, en remplacement d’Alessandro Della Chà. Cette nomination sera effective lors de l’AGM prévu le 24 mai prochain. Cette nomination fait suite à son Capital Market Day réalisé en mars dernier exposant les prochaines étapes de la société et ses ambitions. Mr Di Napoli connait bien la plateforme GI Genius car vient de Medtronic où il a occ...
- Martin Marandon-Carlhian
- Stephane Houri
STMicroelectronics N.V. : A significant downward revision linked to au...
>Q1 2024 results below expectations driven by automotive and an acceleration of the ongoing correction - This morning, STM reported its Q1 2024 results which were clearly below expectations. Revenues were $ 3,465m, down 19,1% q-o-q and down 18.4% y-o-y, below consensus at $ 3.6bn. Guidance was for revenues at $3.6bn, a q-o-q decrease of 15.9%, +/- 350bp. The gross margin was 41.7% also clearly below consensus at 42.3% (guidance was at 42.3% +/- 200bp). EBIT stood at $...
- Martin Marandon-Carlhian
- Stephane Houri
STMicroelectronics N.V. : A significant downward revision linked to au...
>Q1 2024 results below expectations driven by automotive and an acceleration of the ongoing correction - This morning, STM reported its Q1 2024 results which were clearly below expectations. Revenues were $ 3,465m, down 19,1% q-o-q and down 18.4% y-o-y, below consensus at $ 3.6bn. Guidance was for revenues at $3.6bn, a q-o-q decrease of 15.9%, +/- 350bp. The gross margin was 41.7% also clearly below consensus at 42.3% (guidance was at 42.3% +/- 200bp). EBIT stood at $...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.